`
` Address:
`
`
`
`
`
`
`
`
`
`
`
` Date of Birth:
`
` Place of Birth:
`
` Education:
`
`
`
`
`
`
`1978 B.A.
`
`
`
`1982 M.D.
`
`
`Curriculum Vitae
`
`William Curtis Biggs, MD, FACE, ECNU
`
`1215 South Coulter Street
`Suite 400
`Amarillo, TX 79106
`
`November 16, 1956
`
`Merced, California
`
`University of California, San Diego
`Chemistry, Magna cum Laude
`
`University of Texas
`Southwestern Medical School at Dallas
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1982-1983
`
`
`
`1983-1984
`
`
`
`
`
`1985-1986
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Intern in Medicine,
`University of California, San Diego
`
`Junior Assistant Resident,
`New England Deaconess Hospital,
`Boston
`
`Senior Assistant Resident,
`New England Deaconess Hospital,
`Boston
`
`Fellow in Endocrinology/Diabetes
`Joslin Diabetes Center, Boston
`New England Deaconess Hospital,
`Boston
`
`
` Post Doctoral Training:
` Internship and Residencies:
`
`
`
`
`
`
`
`
`1984-1985
`
`
`
`
`
`
`
` Fellowships:
`
`
`
`
`
`
` Licensure and Certification:
`
` Licenses:
`
` 1983
` 1984
`
`
`
`
`
` Texas Board of Medical Examiners (G3157)
` Massachusetts Registry
`
`(52237)
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01675
`
`
`
`
` Board Certification:
`
` 1985
`
`
`2014
`
`
`
`
`
`Internal Medicine - American Board of Internal Medicine
`
`Clinical Informatics – American Board of Preventative Medicine
`
`Endocrine Certification Neck Ultrasound (ECNU)
`American College of Endocrinology
`
`
` Other Certifications:
`
` 2010
`
`
`
`
` Academic Appointments:
`
` 1983-1986 Clinical Fellow in Medicine
`
`
`
`
`
`Harvard Medical School, Boston
`
` 1986-
`
`
`
`
`
`
`
`
`
`
` Hospital Appointments:
`
` 1985-1986
`
`
`
`
` 1986-
`
`
`
`
`
`
`
`
`Clinical Assistant Professor
`
`
`Department of Internal Medicine
`
`
`Texas Tech School of Medicine,
`
`
`Amarillo
`
`New England Baptist Hospital, Boston
`
`Assistant to Chief of Medicine,
`
`Northwest Texas Hospital, Amarillo
`
`Quality Assurance Committee 1987-1989
`
`
`
`
`
`
`Nutrition Committee 1987-1995
`
`Chairman, 1988-1995
`
`Diabetes Center, Medical Advisor 1989- 1999,
`Medical Director 2004 - present
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Department of Internal Medicine
`
`Chairman, 1989- 1993
`
`President of Medical Staff 1994-1995
`
`
`
`and 1995-1996
`
`Baptist St. Anthony’s Hospital, Amarillo
`(formerly High Plains Baptist Hospital)
`
`
`
`Director, Center for Diabetes Care 1988-1991
`
`
`
`
`
`
`
`
` 1986-
`
`
`
`
`
`Pharmacy & Therapeutics Committee 1988-1992
`
`
`
`
`
` Chairman 1990-1992
`
`
`
`
` Memberships in Professional Societies:
`
` 1983-2009
` 1984-1986
` 1986-
`
`
`American College of Physicians
`Massachusetts Medical Society
`Texas Medical Association
`
`2
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01675
`
`
`
`
` 1986-
`
` 1985-
`
`
`
` 1990-1998
` 1991-
`
` 1992-
`
`
`
`
` 2012-
`
`
`Current Positions
`
` 1995-
`
`
`
`
`
`
`
`
`
`
` 2012-
`
`
` 2010-
` 2014-
` 2015-
`
`
`
`
`
`
`
`
`
`1986-1995
`
`
`
`1988-1989
`
`1991-1994
`
`
`
` 2015-
`
`
` 2017 -
`
`
`
`
`Previous Positions
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1994
`
`
`
`
`
`1996 - 2004
`
`
`
`2005- 2011
`
`
`
`
`2009 - 2010
`
`
`
`Potter-Randall County Medical Society
`American Diabetes Association
`
`Council on Diabetes and Pregnancy
`American Society of Internal Medicine
`American Medical Association
`American Association of Clinical Endocrinologists (AACE)
`
`(Charter Member)
`American Medical Informatics Association
`
`Amarillo Medical Specialists, LLP
`Managing Partner and Chief Information Officer
`(Currently a 43 provider medical group)
`
`Amarillo Legacy Medical ACO
`CEO and Chief Medical Officer
`
`
`
`
`American Association of Clinical Endocrinologists
`Socioeconomics Committee
`IT Advisory Committee
`Business Opportunities Committee
`
`American Medical Association CPT Editorial Panel
`AMA CPT Reviewer / Advisor for AACE
`
`Amarillo Hospital District
`Board of Managers - Vice Chairman
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Medical Advisor to U.S. Department of Health & Human
`Services Administrative Law Judges.
`
`Board of Directors, Juvenile Diabetes Foundation, Amarillo
`
`Board of Directors, Amarillo Chapter, American Diabetes
`Association
`
`Health Reform Advisory Committee Member for
`Hon. Bill Sarpalius 13th District – Texas
`
`Board of Governors
`Northwest Texas Healthcare System, Amarillo
`
`Board of Directors, Texas Chapter
`American Association of Clinical Endocrinologists
`
`President , Texas Chapter
`American Association of Clinical Endocrinologists
`
`
`
`3
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01675
`
`
`
`
`2004 - 2014
`
`
`
`Director, Take Control of Your Diabetes Conference
`9/11/2004, 9/16/2006, 2/7/2009, 9/10/2011, 10/18/2014
`Amarillo Civic Center
`
`Session Co-Chair – American Diabetes Association 69th
`Scientific Sessions, New Orleans – “Advances in Our
`Understanding of Continuous Glucose Monitoring”
`
`Participant in AMA Meaningful Use comment meetings
` with CMS, representing the American Association of
`Clinical Endocrinologists
`
`Texas Diabetes Council - Advisor
`Texas Department of State Health Services
`Health Professional Advisory Committee
`Medical Professional Advisory Subcommittee
`
`
`
`
`
`
`
`
`
`
`2009
`
`
`2010
`
`
`
` 2010 - 2015
`
`
`
`
`
`
`
`
`Recent Honors:
`
`
`Who’s Who in Medicine and Healthcare 2nd - 7th editions 1998 – 2008
`
`
`
`
`
`
`
`Who’s Who in America, 55th – 62nd editions, 2001 - 2008
`
`Who’s Who in Science and Engineering, 2002 - 2006
`
`Fellow, American College of Endocrinology 2005
`
`Promise Honoree, Juvenile Diabetes Research Foundation, Amarillo, June 2005
`
`Texas Monthly “SuperDoctor” Texas Monthly Magazine, 2005 through 2019
`
`
`
`
`
`Selected Publications:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Impaired Perception of Inspiratory Resistive Loads in Diabetes Mellitus.
`American Review of Respiratory Disease, 132:4(2) A191, April 1986
`
`Diabetes Mellitus and Exercise. Panhandle Health 3:3 Summer 1992
`
`Transplantation and Diabetes Panhandle Health 9:4 Fall 1999
`
`How to Interpret Your Blood Test Results Medical Tests Sourcebook 2nd ed.,
`Joyce Brennfleck Shannon, editor. Omnigraphics Press, Detroit 2004
`
`Has the TSH “Normal Range” been set too high? Panhandle Health 14:1 Winter
`2003
`
`Obesity and Diabetes Panhandle Health 14:2 Spring 2004
`
`
`
`
`4
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01675
`
`
`
`
`
`‘The Fertile and Infertile Phases of the Menstrual Cycle are Signaled by Cervical-
`Vaginal Fluid Die Swell Functions’ Jian Wang, Ph.D., Stephen J. Usala, M.D.,
`Ph.D., Faye O’Brien-Usala, D.C., William C. Biggs, M.D., Mark W. Vaughn,
`Ph.D., and Gregory B. McKenna, Ph.D. The Endocrinologist
`November/December 2009 19:6 291-297
`
`The EHR Incentive Program and “Meaningful Use” AACE The First Messenger
`19:2 6-27 March/April 2010
`
`“The Elasticity of Cervical-vaginal Secretions is Abnormal in Polycystic Ovary
`Syndrome: Case Report of Five PCOS Women” Nabila Shamim, Stephen J.
`Usala, William C. Biggs, Gregory McKenna Indian Journal of Endocrinology
`and Metabolism - 2012 Nov-Dec; 16(6): 1019–1021
`
`“Vaginal Swab Levels of CA125 are Related to Time of Cycle in Ovulatory
`Women: a Pilot Study” , Stephen J. Usala, M.D., Ph.D., William C. Biggs, M.D.,
`Faye O’Brien-Usala, D.C. Journal of Reproductive Medicine 2015 Jul-Aug;60(7-
`8):287-9
`
`“Optimizing mHealth Technologies in Real-World Clinical Practices”, Pablo
`Mora, William C. Biggs, and Christopher G. Parkin. Clinical Diabetes 2019 July;
`37(3): 269-275
`
`
`
`Selected Recent Oral Presentations:
`
`
`Texas AACE Diabetes Management for Primary Care Physicians All-Day
`Program Speaker and Co-Director
`
`
`2007
`2008
`2009
`
`2010
`
`2011
`
`
`
`
`
`
`
`
`
`Amarillo
`South Padre Island
`Tyler
`Odessa
`Lubbock
`Waco
`El Paso
`
`
`
`
`
`
`
`2009 eClinicalWorks National Users Meeting
`
`Keynote Speaker General Session: “The Future of Healthcare”
`
`Las Vegas, Nevada
`
`2009 American Diabetes Association Scientific Sessions
`Co-chair: “Advances in Our Understanding of Continuous Glucose
`Monitoring”
`New Orleans, LA
`
`2010 “Office Management of Thyroid Nodules”
`Texas Medical Association Annual Meeting, Fort Worth
`
`eClinicalWorks National Users Meeting (Invited Speaker)
`“Clinical Analytics with IBM Cognos / EBO”
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01675
`
`
`
`Orlando, Florida
`
`
`2011 American Association of Clinical Endocrinologists Annual Meeting
`
`“Optimizing Your EHR for Endocrine Practice”
`
`San Diego, California
`
`
`
`eClinicalWorks National Users Meeting
`Using eCW Technology to Minimize Paper, Increase Efficiency, Increase
`Quality of Care, and Improve Income
`Scottsdale, AZ
`
`
`2012 American Association of Clinical Endocrinologists Annual Meeting
`“Exploring Alternative Payment Mechanisms – The Patient Centered
`Medical Home”
`Philadelphia, Pennsylvania
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`eClinicalWorks National Users Meeting
`“Specialist Panel – Specialty Physicians Share Their Best Practices with
`eCW”
`Washington, DC
`
`
`
` 2013 American Association of Clinical Endocrinologists Annual Meeting
`
`“How Will Endocrinologists Be Paid - The Role of the Accountable Care
`Organization”
`Phoenix, Arizona
`
`
`
`
`
`
`
`
`eClinicalWorks National Users Meeting (Invited Speaker)
`“IT implementation in an Accountable Care Organization – HIE, Care
`Coordination, Clinical Analytics, Financial Analytics”
`San Antonio, Texas
`
`2014 HIMSS Texas annual meeting
`
`IT Challenges – Implementing a Physician Directed ACO in Amarillo, TX
`
`Dallas, Texas
`
`
`
`
`
`National Association of ACOs
`Putting the Pieces Together – A Physician Directed ACO in Amarillo, TX
`Baltimore, MD
`
`American Association of Clinical Endocrinologists Annual Meeting
`The Endocrinologist’s role in ACOs
`Las Vegas, NV
`
`
`
`
`
`
`
`
`
`
`
`
`
` 2015
`
`
` 2016
`
`
`6
`
`
`
`PCMH and Shared Savings ACO Summit
`Achieving Success with a Physician Led ACO
`Nashville, TN
`
`
`HIMSS 15 – Chicago
`IT Challenges in a Physician Directed ACO
`
`American Association of Clinical Endocrinologists Annual Meeting
`Socioeconomic Forum – How does the endocrinologist fit into an ACO?
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01675
`
`
`
`
`
`
` 2017
`
`
`
`
`
`2018
`
`
`2019
`
`
`
`Orlando, FL
`
`HIMSS Texas annual meeting - San Antonio, Texas
`Implementing a Remote Glucose Monitoring Program using Internet Connected
`BG Meters and Care Coordinators in an Accountable Care Organization
`San Antonio, Texas
`
`eClinicalWorks National Users Conference – Nashville, TN
`Panel Discussion : “Impact of proposed CMS revisions to E&M codes”
`
`American Association of Clinical Endocrinologists Annual Meeting – Los
`Angeles CA – “Telehealth – Expanding Your Reach”
`
`
`
`Selected Recent and Current Clinical Trials
`
`Principal Investigator
`
`
`
`
`
`
`Sanofi
`
`EFC12405
`
`A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm,
`Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the
`Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With
`or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM) /
`LixiLan-L
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`LPS14347
`
`A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to
`Assess the Clinical and Health Outcomes of Toujeo Compared to
`Commercially Available Basal Insulins for Initiation of Therapy in Insulin -
`naive Patients With Uncontrolled Type 2 Diabetes Mellitus
`
`
`
`AstraZeneca
`
`MB102-229
`
`MB102-230
`A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group,
`Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on
`to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus
`
`Dexcom
`
`DiaMonD
`Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes
`
`NovoNordisk
`
`NN9535-3625 SUSTAIN
`
`Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once
`Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve
`Subjects With Type 2 Diabetes
`
`
`
`7
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01675
`
`
`
`
`
`NN9535-3627 SUSTAIN
`
`NN1218-3852 ONSET
`
`Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination
`With Insulin Detemir in Adults With Type 1 Diabetes
`
`
`
`NN1218-3854 ONSET 5
`NN2211-3916 BEGIN
`
`Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes
`Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
`
`
`
`NN9211-3919 ADJUNCT
`
`The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the
`Treatment of Type 1 Diabetes
`
`
`
`
`
`NN1250-3995 IMPACT / SWITCH 1
`
`A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin
`Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1
`Diabetes
`
`NN9211-4083 ADJUNCT 2
`
`
`
`
`
`NN1218-4131 ONSET 8
`NN9924-4222 PIONEER 3
`NN9924-4234 PIONEER 5
`
`Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in
`Subjects With Type 2 Diabetes
`
`
`
`NN1250-4252
`
`A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin
`Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately
`Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8
`
`
`
`Mylan Ex.1049
`Mylan v. Sanofi - IPR2018-01675
`
`